




## Mouse Anti-Human IgG<sub>2</sub> Fc

| Cat. No. | Format                               | Size   |
|----------|--------------------------------------|--------|
| 9070-01  | Purified (UNLB)                      | 0.5 mg |
| 9070-02  | Fluorescein (FITC)                   | 0.5 mg |
| 9070-04  | Alkaline Phosphatase (AP)            | 1.0 mL |
| 9070-08  | Biotin (BIOT)                        | 0.5 mg |
| 9070-09  | R-phycoerythrin (PE)                 | 0.1 mg |
| 9070-30  | Alexa Fluor <sup>®</sup> 488 (AF488) | 0.1 mg |
| 9070-31  | Alexa Fluor <sup>®</sup> 647 (AF647) | 0.1 mg |
| 9070-32  | Alexa Fluor <sup>®</sup> 555 (AF555) | 0.1 mg |



ELISA plate was coated with purified human IgG1, IgG2, IgG3, and IgG4. Immunoglobulins were detected with serially diluted Mouse Anti-Human IgG<sub>2</sub> Fc-BIOT (SB Cat. No. 9070-08) followed by Streptavidin-HRP (SB Cat. No. 7100-05).

### Overview

|                    |  |
|--------------------|--|
| <b>Clone</b>       | HP6002                                 |
| <b>Isotype</b>     | Mouse (BALB/c) IgG <sub>1κ</sub>       |
| <b>Immunogen</b>   | Human IgG <sub>2</sub> myeloma protein |
| <b>Specificity</b> | Human IgG <sub>2</sub> Fc; Mr 146 kDa  |

### Applications

ELISA – Quality tested <sup>2,7</sup>  
 FLISA – Quality tested  
 ELISPOT – Reported in literature <sup>2,8</sup>  
 FC – Reported in literature <sup>13</sup>  
 IHC-FS – Reported in literature <sup>9,10</sup>  
 WB – Reported in literature <sup>9,11,12</sup>  
 IP – Reported in literature <sup>1</sup>  
 Multiplex – Reported in literature <sup>14,15</sup>  
 Purification – Reported in literature <sup>16</sup>  
 SPR – Reported in literature <sup>17</sup>

### Working Dilutions

|                           |  |                    |
|---------------------------|--|--------------------|
| <b>ELISA</b>              | AP conjugate   | 1:500 – 1:1,000    |
|                           | BIOT conjugate   | 1:5,000 – 1:20,000 |
| <b>FLISA</b>              | FITC, AF488, and AF555 conjugates  | 1:200 – 1:400      |
|                           | PE and AF647 conjugates  | ≤ 1 µg/mL          |
| <b>Other Applications</b> | Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need. |                    |

**For Research Use Only. Not for Diagnostic or Therapeutic Use.**

## Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl<sub>2</sub>/50% glycerol, pH 8.0, containing NaN<sub>3</sub> as preservative. Store at 2-8°C or long-term at -20°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN<sub>3</sub> and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Alexa Fluor® 488 (AF488), Alexa Fluor® 555 (AF555), and Alexa Fluor® 647 (AF647) conjugates are supplied as 0.1 mg in 0.2 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

## Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

## References

1. Reimer CB, Phillips DJ, Aloisio CH, Moore DD, Galland GG, Wells TW, et al. Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. *Hybridoma*. 1984;3:263-75. (Immunogen, IP)
2. Næss LM, Aarvak T, Aase A, Oftung F, Høiby EA, Sandin R, et al. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. *Vaccine*. 1999;17:754-64. (ELISA, ELISPOT)
3. Kobayashi T, van der Pol W, van de Winkel JG, Hara K, Sugita N, Westerdaal NA, et al. Relevance of IgG receptor IIIb (CD16) polymorphism to handling of *Porphyromonas gingivalis*: implications for the pathogenesis of adult periodontitis. *J Periodontol Res*. 2000;35:65-73. (ELISA)
4. Lightle S, Aykent S, Lacker N, Mitaksov V, Wells K, Zobel J, et al. Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. *Protein Sci*. 2010;19:753-62. (ELISA)
5. Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. *Clin Cancer Res*. 2012;18:6497-508. (ELISA)
6. Einarsdottir HK, Stapleton NM, Scherjon S, Andersen JT, Rispens T, van der Schoot CE, et al. On the perplexingly low rate of transport of IgG2 across the human placenta. *PLoS One*. 2014;9(9):e108319. (ELISA)
7. Ferreira AR, Singh B, Cabrera-Mora M, Magri De Souza AC, Queiroz Marques MT, Porto LC, et al. Evaluation of naturally acquired IgG antibodies to a chimeric and non-chimeric recombinant species of *Plasmodium vivax* reticulocyte binding protein-1: lack of association with HLA-DRB1\*/DQB1\* in malaria exposed individuals from the Brazilian Amazon. *PLoS One*. 2014;9(8):e105828. (ELISA)
8. Carson PJ, Schut RL, Simpson ML, O'Brien J, Janoff EN. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. *J Infect Dis*. 1995;172:340-5. (ELISPOT)
9. Mongan LC, Ockleford CD. Behaviour of two IgG subclasses in transport of immunoglobulin across the human placenta. *J Anat*. 1996;188:43-51. (IHC-FS, WB)
10. Greenlee JE, Boyden JW, Pingree M, Brashear HR, Clawson SA, Keeney PM. Antibody types and IgG subclasses in paraneoplastic neurological syndromes. *J Neurol Sci*. 2001;184:131-7. (IHC-FS)
11. Harada S, Hata S, Kosada Y, Kondo E. Identification of epitopes recognized by a panel of six anti-human IgG2 monoclonal antibodies. *J Immunol Methods*. 1991;141:89-96. (WB)
12. Dibart S, Eftimiadi C, Socransky S, Taubman MA, van Dyke TE. Rapid evaluation of serum and gingival crevicular fluid immunoglobulin G subclass antibody levels in patients with early-onset periodontitis using checkerboard immunoblotting. *Oral Microbiol Immunol*. 1998;13:166-72. (WB)
13. Gao B, Moore C, Porcheray F, Rong C, Abidoglu C, DeVito J, et al. Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. *Am J Transplant*. 2014;14:1581-91. (FC)
14. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. *Liver Transpl*. 2012;18:984-92. (Multiplex)
15. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. *Transplantation*. 2013;95:1113-9. (Multiplex)
16. Keen J, Serghides L, Ayi K, Patel SN, Ayisi J, van Eijk A, et al. HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. *PLoS Med*. 2007;4(5):e181. (Purification)
17. Lewis KB, Hughes RJ, Epstein MS, Josephson NC, Kempton CL, Kessler CM, et al. Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. *PLoS One*. 2013;8(5):e61120. (Surface Plasmon Resonance)

Alexa Fluor® 488, 647, and 555 are provided under an Intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For information on purchasing a license to this product for any other use, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or [outlicensing@lifetech.com](mailto:outlicensing@lifetech.com).